Telomir Pharmaceuticals (NASDAQ:TELO) Shares Up 0.8% – Time to Buy?

Shares of Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) shot up 0.8% during mid-day trading on Friday . The company traded as high as $1.27 and last traded at $1.24. Approximately 53,204 shares were traded during mid-day trading, a decline of 63% from the average session volume of 145,492 shares. The stock had previously closed at $1.23.

Wall Street Analyst Weigh In

Several research firms have recently commented on TELO. Weiss Ratings restated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a report on Tuesday, April 21st. Zacks Research raised Telomir Pharmaceuticals to a “hold” rating in a research report on Wednesday, March 18th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Telomir Pharmaceuticals Stock Up 0.8%

The business has a 50-day simple moving average of $1.30 and a two-hundred day simple moving average of $1.30. The company has a market cap of $85.29 million, a price-to-earnings ratio of -4.28 and a beta of -0.24.

Telomir Pharmaceuticals (NASDAQ:TELO) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.04.

Hedge Funds Weigh In On Telomir Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new stake in shares of Telomir Pharmaceuticals in the second quarter worth $95,000. Raymond James Financial Inc. raised its holdings in Telomir Pharmaceuticals by 4,101.9% in the 3rd quarter. Raymond James Financial Inc. now owns 75,340 shares of the company’s stock worth $105,000 after acquiring an additional 73,547 shares during the period. Jane Street Group LLC bought a new position in Telomir Pharmaceuticals in the 2nd quarter worth $62,000. XTX Topco Ltd acquired a new position in Telomir Pharmaceuticals during the 4th quarter worth $53,000. Finally, World Investment Advisors acquired a new position in Telomir Pharmaceuticals during the 4th quarter worth $47,000.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc (NASDAQ: TELO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company’s lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.